Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 9, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

December 17, 2018

Conditions
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome
Interventions
BIOLOGICAL

ATIR101

T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).

PROCEDURE

Haploidentical hematopoietic stem cell transplantation (HSCT)

"CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:~* Total Body Irradiation (TBI) regime~* Non-TBI regime~(See below for details)"

PROCEDURE

TBI regime

"* Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)~* Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."

PROCEDURE

Non-TBI regime

"* Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4~* Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7~* Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1~* ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV."

Trial Locations (11)

1000

Institut Jules Bordet, Brussels

3000

Universitair Ziekenhuis Gasthuisberg, Leuven

4000

Centre Hospitalier Universitaire de Liège, Liège

8000

Algemeen Ziekenhuis Sint-Jan, Bruges

10000

University Hospital Centre Zagreb, Zagreb

55131

University Medical Center Mainz, Mainz

L8V 1C3

Juravinski Hospital and Cancer Centre, Hamilton

H1T 2M4

Maisonneuve-Rosemont Hospital, Montreal

1649-028

Hospital de Santa Maria, Clinica Universitaria Hematologia, Lisbon

B9 5SS

Heartlands Hospital, Birmingham

W12 ONN

Hammersmith Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Kiadis Pharma

INDUSTRY

NCT02500550 - Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor | Biotech Hunter | Biotech Hunter